Participants 88 136 8
normotensive patients with advanced malignancies
Participants 286 310 6
advanced cancer patients
Participants 445 490 7
41 normotensive advanced solid tumor patients
Participants 1039 1060 5
gs in normotensive pa
Participants 1131 1217 3
tion. Patients have intrinsic differences in sensitivity to sorafenib's BP-elevating e
